Action 002793 LUOXIN PHARMACEUTICALS GROUP STOCK CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Luoxin Pharmaceuticals Group Stock Co., Ltd.

Actions

002793

CNE1000026S7

Cours en clôture Shenzhen S.E.
Autres places de cotation
 00:00:00 15/05/2024 		Varia. 5j. Varia. 1 janv.
5,06 CNY +3,69% Graphique intraday de Luoxin Pharmaceuticals Group Stock Co., Ltd. +5,20% -5,60%
26/04 Luoxin Pharmaceuticals Group Stock Co. publie ses résultats pour le premier trimestre clos le 31 mars 2024 CI
08/03 Luoxin Pharma obtient le droit d'utiliser la technologie de transplantation de microbiote fécal de Shenzhen Shishijijun Biotechnology MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology
Tranche Update on Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback Plan announced on February 2, 2024.
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback announced on February 2, 2024, has closed with 26,027,861 shares, representing 2.39% for CNY 99.99 million.
Luoxin Pharmaceuticals Group Stock Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.
Luoxin Pharmaceuticals Group Stock Co., Ltd. authorizes a Buyback Plan.
Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial
Two Luoxin Pharma Drugs Selected in China’s National Drug Procurement Program
Luoxin Health Technology Development Co., Ltd. announced that it has received CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s LX-039 (Innovative Anti-Tumor Drug) Phase I Clinical Study Data Presented At ESMO 2023
Luoxin Pharmaceuticals Group Stock Co., Ltd. agreed to acquire additional unknown stake in Luoxin Health Technology Development Co., Ltd. from Chengdu Deyi Xinhua Equity Investment Partnership Enterprise (LP) and Deyi Investment Management Co., Ltd. for CNY 1.
Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Luoxin Pharmaceuticals Group Stock Co., Ltd. Elects Li Meng as Non-Independent Directors
Luoxin Pharmaceuticals' Injection Passes Regulatory Consistency Evaluation
Luoxin Pharmaceuticals Gets Regulatory Nod for Anti-Baterial Infection Drug
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 002793
  4. Actualités Luoxin Pharmaceuticals Group Stock Co., Ltd.
  5. Autres langues